Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109, USA.
Int J Mol Sci. 2024 Mar 19;25(6):3431. doi: 10.3390/ijms25063431.
Premature loss of ovarian function (POI) is associated with numerous negative side effects, including vasomotor symptoms, sleep and mood disturbances, disrupted urinary function, and increased risks for osteoporosis and heart disease. Hormone replacement therapy (HRT), the standard of care for POI, delivers only a subset of ovarian hormones and fails to mimic the monthly cyclicity and daily pulsatility characteristic of healthy ovarian tissue in reproductive-aged individuals whose ovarian tissue contains thousands of ovarian follicles. Ovarian tissue allografts have the potential to serve as an alternative, cell-based HRT, capable of producing the full panel of ovarian hormones at physiologically relevant doses and intervals. However, the risks associated with systemic immune suppression (IS) required to prevent allograft rejection outweigh the potential benefits of comprehensive and dynamic hormone therapy. This work investigates whether the age of ovarian tissue donor animals affects the function of, and immune response to, subcutaneous ovarian grafts. We performed syngeneic and semi-allogeneic ovarian transplants using tissue from mice aged 6-8 (D7) or 20-22 (D21) days and evaluated ovarian endocrine function and immune response in a mouse model of POI. Our results revealed that tissue derived from D7 donors, containing an ample and homogeneous primordial follicle reserve, was more effective in fully restoring hypothalamic-pituitary-ovarian feedback. In contrast, tissue derived from D21 donors elicited anti-donor antibodies with higher avidity compared to tissue from younger donors, suggesting that greater immunogenicity may be a trade-off of using mature donors. This work contributes to our understanding of the criteria donor tissue must meet to effectively function as a cell-based HRT and explores the importance of donor age as a factor in ovarian allograft rejection.
卵巢功能早衰(POI)与许多负面副作用有关,包括血管舒缩症状、睡眠和情绪障碍、排尿功能障碍以及骨质疏松症和心脏病风险增加。激素替代疗法(HRT)是 POI 的标准治疗方法,只能提供卵巢激素的一部分,并且不能模拟生殖期个体健康卵巢组织的每月周期性和每日脉冲性,这些个体的卵巢组织中含有数千个卵泡。卵巢组织同种异体移植物有可能成为替代的、基于细胞的 HRT,能够以生理相关的剂量和间隔产生完整的卵巢激素谱。然而,为了防止同种异体移植物排斥而需要进行的全身免疫抑制(IS)的风险超过了全面和动态激素治疗的潜在益处。这项工作研究了供体动物的卵巢组织年龄是否会影响皮下卵巢移植物的功能和对其的免疫反应。我们使用来自 6-8 天(D7)或 20-22 天(D21)龄的小鼠的组织进行了同基因和半同种异体卵巢移植,并在 POI 的小鼠模型中评估了卵巢内分泌功能和免疫反应。我们的结果表明,来自 D7 供体的组织,含有丰富且均匀的原始卵泡储备,更有效地完全恢复下丘脑-垂体-卵巢反馈。相比之下,来自 D21 供体的组织与来自年轻供体的组织相比,引起抗供体抗体的亲和力更高,这表明更高的免疫原性可能是使用成熟供体的权衡取舍。这项工作有助于我们理解作为基于细胞的 HRT 有效发挥作用的供体组织必须满足的标准,并探讨了供体年龄作为卵巢同种异体移植物排斥的一个因素的重要性。